Results 101 to 110 of about 36,119 (263)

Bisphosphonate- and disumab-related gingival disorders: case analysis from the U.S. Food and Drug Administration Adverse Event Reporting System

Frontiers in Endocrinology
Prior research has indicated that bisphosphonates (BPs) can improve periodontal disease because of their anti-osteoporosis properties. In vitro studies have shown that BPs induce cytotoxicity, inhibit wound healing, and thus affect periodontal disease ...
Lei Wang, Wei Zhang, Cheng-long Zhao, Zhong-hua Fu   +3 more
doaj   +1 more source

Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab

Kidney & Blood Pressure Research, 2019
Background: Studies in women with post-menopausal osteoporosis have shown that discontinuation of treatment with denosumab leads to an increased risk of vertebral fractures because of rebound bone turnover and rapid loss of bone mineral density (BMD ...
Claudia Kobel, Diana Frey, Nicole Graf, Rudolf P. Wüthrich, Marco Bonani   +4 more
doaj   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 422-444, February 2026.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source

New molecular targets in bone metastases [PDF]

, 2010
Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis.
Colucci, G., Fratto, M., Galluzzo, S., Gucciardino, C., LOMBARDI, LUCIO, Maiello, E., Pantano, F., Riva, E., RIZZO, Sergio, RUSSO, Antonio, SANTINI, Daniele, Silvestris, N., Tonini, G., Vincenzi, B., Zoccoli, A.   +14 more
core   +1 more source

THU445 Complicated Course And Management After Denosumab Discontinuation: A Case Report [PDF]

, 2023
Ipsa Arora, Lisa Ceglia
openalex   +1 more source

New cell lines expanding the diversity of Ewing sarcoma models

International Journal of Cancer, Volume 158, Issue 3, Page 642-655, 1 February 2026.
What's new? A chromosomal translocation between the EWSR1 and ETS genes is the key oncogenic driver in Ewing sarcoma. EWSR1::FLI1, the most frequent fusion, is subdivided into different fusion types with unclear prognostic relevance. Here, the authors describe the establishment and characterization of four new, intrinsically immortal, patient‐derived ...
Maximilian Kerkhoff, Christiane Schaefer, Wilhelm G. Dirks, Dawid Krzeciesa, Maximilian Bretschneider, Pauline R. Plaumann, Wiebke K. Guder, Arne Streitbürger, Sonja Herter, Heike Peterziel, Ina Oehme, Felina Zahnow, Thomas G. P. Grünewald, Uta Dirksen   +13 more
wiley   +1 more source

The Effect of RANKL/OPG Balance on Reducing Implant Complications [PDF]

, 2017
Despite the phenomenal success of implants particularly in the realms of dentistry and orthopaedics, there are still challenges to overcome. The failure of implants resulting from infection, prosthetic loosening, and non-union continue to be the most ...
Giannoudis, P.V., Hatton, P.V., Jia, X., Kapasa, E.R., Yang, X.B.   +4 more
core   +3 more sources

Supplementary Figure 1 from Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

, 2023
Daniel Branstetter, Scott D. Nelson, J. Carlos Manivel, Jean‐Yves Blay, Sant P. Chawla, David M. Thomas, Susie Jun, Ira Jacobs   +7 more
openalex   +1 more source

Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
This figure emphasizes current understanding of the regulatory networks, approach of diagnose, available preclinical models and clinical management of bone metastasis. to guide future therapeutic development. A deep understanding of these aspects enables the prevention of bone metastasis and the implementation of effective therapeutic strategies ...
Jingyuan Wen, Binghua Li, Shengjia Wang, Yongzhong Yao, Zhao Huang, Decai Yu   +5 more
wiley   +1 more source

Severe Hypocalcemia and Hypomagnesemia with Denosumab in Advanced Chronic Kidney Disease: Case Report and Literature Review

Case Reports in Oncological Medicine, 2018
Background. Denosumab has become the preferred agent over zolendronic acid to help prevent skeletal-related events in patients with metastatic bone disease and multiple myeloma because it is approved for use in those with kidney dysfunction.
Christina F. Marlow, Shailendra Sharma, Faizan Babar, Jianqing Lin   +3 more
doaj   +1 more source